Kalydeco (also known as Kalydeco or VX-770) is a drug for the treatment of cystic fibrosis, developed by Vertex Pharmaceuticals and the Cystic Fibrosis Foundation. FDA approved on January 31, 2012.
Kalydeco is a cystic fibrosis transmembrane conductance regulator (CFTR). In patients with the G551D mutation, Kalydeco, a pill taken two times a day with fat-containing food, helps the protein made by the CFTR gene function better and as a result, improves lung function and other aspects of CF such as increasing weight gain.
There have been no reports of overdose with Kalydeco. The highest single dose used in a clinical study was 800 mg in a solution formulation without any treatment-related adverse events.
Strength: 150 Mg
Pill Imprint: V 150
View Images & Details